clinical trials

Medicine

Excess Miro1 Protein Drives Insulin Resistance in Skeletal Muscle

A protein called Miro1 acts as a direct driver of insulin resistance when it accumulates in skeletal muscle, according to research from the Pennington Biomedical Research Center. Preclinical removal of the protein restored normal muscle response to insulin, highlighting a new biological target for biomedical innovation and future drug discovery.

Medicine

Chemogenetic Gene Therapy Dampens Brain Cell Activity to Control Epilepsy

A research team in China has treated three epilepsy patients with a novel gene therapy that allows a drug to dampen brain cell activity. The trial represents the first reported clinical use of a chemogenetic approach to reduce seizures. The study demonstrates how combining genetic modification with targeted pharmaceutical control can suppress abnormal neural firing.

Medicine

Off-the-shelf CAR natural killer cells enter lymphoma trial in South Africa

Clinical researchers in Johannesburg are evaluating donor-derived natural killer cells engineered to treat resistant B-cell non-Hodgkin lymphoma. The phase 1 study, named QUILT-106, tests whether cell lines grown in a laboratory can bypass the complex manufacturing required for individualized autologous therapies. This medical innovation could broaden access to cellular immunotherapies across regions where conventional personalized treatments remain difficult to deliver.

Medicine

Silver Diamine Fluoride Halts Childhood Cavities Without Drilling

A major multi-site clinical trial led by researchers at the University of Michigan has confirmed that painting teeth with silver diamine fluoride can arrest tooth decay in young children without drilling, injections, or sedation. The clinical discovery, published in JAMA Pediatrics, offers a low-cost medical innovation that could prevent severe dental pain and hospital surgeries for thousands of pediatric patients.

Giovanni Sapere

Medicine

Personalized mRNA Melanoma Vaccine Cuts Recurrence Risk by 42%

In an international Phase III trial, adding the personalized therapeutic vaccine intismeran to pembrolizumab immunotherapy reduced the risk of recurrence or death by 42% in high-risk melanoma patients after surgery. Presented at the ESMO Congress 2026, the findings establish a new therapeutic approach combining tailored neoantigen targeting with immune checkpoint blockade. This medical innovation offers post-surgical protection for patients facing high chances of cancer relapse.

Giovanni Sapere

Medicine

Nanorobots: What it is and how it works

Nanorobots are nanoscale devices designed to perform specific tasks within the human body, such as targeted drug delivery, repairing damaged tissue, or eliminating cancer cells. Thanks to their extremely small size, nanorobots can navigate through the circulatory system and directly penetrate…

Mattia Sapere